Vyvanse shortage ‘resolved’

TGA declares supply issues impacting ADHD medication Vyvanse to be “resolved”  Takeda Pharmaceuticals Australia is reporting that supply shortages are no longer impacting its Vyvanse (lisdexamfetamine dimesilate) capsules.  Shortages had impacted various strengths of the medication, with the Therapeutic Goods Administration (TGA) reporting that supplies of Vyvanse 50mg capsules had been resolved as of 7 March,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Actions speak louder than words
Next Harmonise RSV vax rules: PSA